Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report

Tyrosine kinase inhibitor therapy is an established standard of care for patients with NSCLC with EGFR mutations, but a worse prognosis has been observed in patients with specific EGFR exon-20 insertion mutations. Mobocertinib (TAK-788) is a novel tyrosine kinase inhibitor developed to target EGFR e...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Josette Kamel, BA, Natalie Meeder, BA, Sandra Cuellar, PharmD, BCOP, David Chan, PharmD, PhD, Michael Huber, MD, MS, Mary Pasquinelli, DNP, Alicia Hulbert, MD, Karam Khaddour, MD, Lawrence Feldman, MD
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Tyrosine kinase inhibitors Non–small cell lung cancer Exon-20 insertion Mobocertinib CNS neurotoxicity Case report Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/61551415e3464b25acbfc6de48caa7de
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report

Ejemplares similares